US 7,923,212 B2Granted

Antibodies to cytokine receptor zalpha11

AssigneeZymoGenetics, Inc.

InventorsScott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond

Life of this patent

Estimating the term…

Loading patent…

Abstract

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims12

Dependent claims

An isolated antibody which specifically binds to a polypeptide as shown in SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number 538 (Ser), wherein said antibody specifically binds to a fragment of said polypeptide, said fragment consisting of a sequence of amino acid residues selected from the group consisting of:

(a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 101 (Leu) to amino acid number 122 (Gly);
(b) the amino acid sequence as shown in SEQ TD NO:2 from amino acid number 141 (Asn) to amino acid number 174 (Ala);
(c) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 193 (Cys) to amino acid number 261 (Val);
(d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 51 (Trp) to amino acid number 61 (Glu);
(e) the amino acid sequence as shown in SEQ ID NO:2 from amino acid 136 (Ile) to amino acid number 143 (Glu);
(f) the amino acid sequence as shown in SEQ ID NO:2 from amino acid 187 (Pro) to amino acid number 195 (Ser);
(g) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 223 (Phe) to amino acid number 232 (Glu);
and
(h) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 360 (Glu) to amino acid number 368 (Asp);
wherein said antibody is selected from (i) a genetically engineered intact antibody or fragment and (ii) a humanized antibody.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application: 12/623,651Filed 23 Nov 2009 · continuation
Priority: 23 Sep 1998
Published: US 2010/0222556 A12 Sep 2010
Granted: 12 Apr 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07H 21/04
Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of…: with…
C07K 14/715
Receptors; Cell surface antigens; Cell surface determinants: for cytokines; for lymphokines; for interferons
C07K 16/1232
Enterobacterales , e.g. Citrobacter , Serratia , Proteus , Providencia , Morganella or Yersinia: escherichia
C07K 16/2866
Against receptors, cell surface antigens or cell surface determinants: against receptors for cytokines, lymphokines, interferons

Family

Application60/100,896Us provisional application · filed 23 Sep 1998
Application60/123,546Us provisional application · filed 9 Mar 1999
Application60/142,574Us provisional application · filed 6 Jul 1999
Application09/404,641Parent of this division · filed 23 Sep 1999
Application10/715,998Parent of this division · filed 18 Nov 2003
Application11/537,835Parent of this continuation · filed 2 Oct 2006
US 2010/0222556 A1Pre-grant publication · published 2 Sep 2010
US 7,638,286 B2Parent of this continuation
US 7,411,056 B2Parent of this division
Application11/537,835Parent of this division
US 6,576,744 B1Parent of this division
US 2004/0204562 A1Published application
US 2007/0178096 A1Published application
US 7,923,212 B2This patent

From the US filing history. Foreign family members aren’t listed.